• CAS Science Spotlight Home
• About
• What's New

Home   •   Spotlight  •  medsci04  •  Most Cited Journal Articles 2004-Medical Sciences (10)

Most Cited Journal Articles 2004-Medical Sciences

Following is a CAS database record representing a highly cited journal article.

---

CAS subject entries for this document include: Gene, animal; Immunostimulants; Angiogenesis; and 4 additional concepts.

CAPLUS COPYRIGHT 2005 ACS on STN

TITLE:	Gene expression profiling predicts clinical outcome of breast cancer
AUTHOR(S):	van't Veer, Laura J.; Dal, Hongyue; van de Vijver, Marc; He, Yudong D.; Hart, Augustinus A. M.; Mao, Mao; Petersar, Hans L.; van der Kooy, Karin; Marton, Matthew J.; Witteveen, Anke T.; Schrelber, George J.; Kerkhoven, Ron M.; Roberts, Chris; Linsley, Peter S.; Bernards, Rene; Friend, Stephen H.
CORPORATE SOURCE:	Radiotherapy and Molecular Carcmnogenesrs and Centerfor Biomedical Generics, The Netherlands Cancer Institute, Amsterdam, 1066 CX, Neth.
SOURCE:	Nature (London, United Kingdom) (2002), 415(6871), 530-536 CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER:	Nature Publishing Group
LANGUAGE:	English

ABSTRACT:
Breast cancer patients with the same stage of disease can have markedly different treatment responses and overall outcome. The strongest predictors for metastases (for example, lymph node status and histol. grade) fail to classify accurately breast tumors according to their clin. behavior. Chemotherapy or hormonal therapy reduces the risk of distant metastases by approx. one-third; however, 70-80% of patients receiving this treatment would have survived without it. None of the signatures of breast cancer gene expression reported to date allow for patient-tailored therapy strategies. Here we used DNA microarray anal. on primary breast tumors of 117 young patients, and applied supervised classification to identify a gene expression signature strongly predictive of a short interval to distant metastases ('poor prognosis' signature) in patients without tumor cells in local lymph nodes at diagnosis (lymph node neg.). In addn., we established a signature that identifies tumors of BRCA1 carriers. The poor prognosis signature consists of genes regulating cell cycle, invasion, metastasis and angiogenesis. This gene expression profile will outperform all currently used clin. parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy.